Regulatory Pathway for Licensing Biotherapeutics in Mexico-Reference-Cited by-同舟云学术

Regulatory Pathway for Licensing Biotherapeutics in Mexico

Published:2018-09-25 Issue: Volume:5 Page:
ISSN:2296-858X
Container-title:Frontiers in Medicine
language:
Short-container-title:Front. Med.

Author:

López-Morales Carlos A.,Tenorio-Calvo Alejandra,Cruz-Rodríguez Rodolfo,Sánchez y Tepoz Julio,Belgharbi Lahouari,Pérez-Tapia Sonia Mayra,Medina-Rivero Emilio

Publisher

Frontiers Media SA

Subject

General Medicine

Reference39 articles.

1. Biologicals and biosimilars: a review of the science and its implications;Declerck;GaBI J.,2012

2. Recent advances in (therapeutic protein) drug development;Lagassé;F1000Res,2017

3. Review on the worldwide regulatory framework for biosimilars focusing on the Mexican case as an emerging market in Latin America;Ibarra-Cabrera;Biotechnol Adv.,2013

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Navigating Global Regulatory Requirements for Generic Drugs: A Comparative Study of MIST, BRICS, and ICH Countries;International Journal of Pharmaceutical Investigation;2023-12-27

2. Dynamics of biosimilar uptake in emerging markets;Expert Opinion on Biological Therapy;2022-05-22

4. Regulatory considerations in biosimilars: Latin America region;Preparative Biochemistry & Biotechnology;2021-02-01

5. Regulatory and strategic considerations for addressing immunogenicity and related responses in biopharmaceutical development programs;Journal of Clinical and Translational Science;2020-06-15